Special Issue "Melanoma Screening and Therapeutic Prevention (Chemoprevention) in High-Risk Groups"
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 8035
Interests: public health; melanoma; costs; healthcare system optimization; clinical pathways
Interests: melanoma; target therapies; precision medicine; surgical quality
Interests: special populations; stigmatization and psychodermatology; hidradenitis suppurativa; systemic inflammation; dermatoepidemiology; multi-omics integration; machine learning; artificial intelligence; big data; biologics; systemic treatments
Special Issues, Collections and Topics in MDPI journals
Special Issue in Healthcare: COVID-19 in Medicine
Special Issue in Nutrients: Nutrients in Dermatology and Oral Diseases
Malignant cutaneous melanoma has shown one of the fastest growing incidence rates globally, and it has been demonstrated that it is expected to continue to rise. Melanoma is thus an important public health issue as well as an economic concern giving the new high-priced treatment options for advanced stages of melanoma. Considering this latest evidence on epidemiological changes and new target therapies, innovative studies on the effectiveness and cost-effectiveness of melanoma screening are warranted to evaluate if it is time to justify a screening campaign in general or in high-risk population groups.
Moreover, novel studies evaluating the efficacy and effectiveness of chemoprevention (i.e., nicotinamide, statins, fibrates, vitamin D) enrolling higher-risk individuals should be useful to assist clinicians and healthcare commissioners in melanoma cancer control. High-risk patients deserve particular attention and more accurate guidelines based on the best evidence.
This Special Issue calls for trials or real-world data studies on these two relevant arguments to shape a new public health scenario of melanoma.
Prof. Dr. Alessandra Buja
Prof. Dr. Simone Mocellin
Dr. Giovanni Damiani
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- primary prevention
- secondary prevention